Vanda Pharmaceuticals Inc (VNDA)

02:19 AM

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

02:19 AM

08:20 AM

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

08:20 AM

Nov 04, 2024

Brokers Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024

Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024

Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024

Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024

Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024

Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024

Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024

Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024

Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024

Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024

Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024

Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024

Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024

Oct 16, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Oct 16, 2024

Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024

Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024

Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024

Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024

Oct 14, 2024

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals - WHBL

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid By Investing.com - Investing.com UK

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - PR Newswire

Oct 14, 2024

Oct 14, 2024

Vanda Pharma stock soars as Cycle Pharma reiterates $8/share offer - Seeking Alpha

Oct 14, 2024

Oct 14, 2024

Cycle Pharmaceuticals offers $8 per share for Vanda By Investing.com - Investing.com UK

Oct 14, 2024

Oct 14, 2024

Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda - AllSides

Oct 14, 2024

Oct 13, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. - Marketscreener.com

Oct 13, 2024

Oct 11, 2024

Profit Investment Management LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 11, 2024

Oct 10, 2024

Squarepoint Ops LLC Decreases Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.

Oct 09, 2024

Oct 07, 2024

US Supreme Court reportedly declines to hear Vanda patent case - MSN

Oct 07, 2024

Oct 07, 2024

Dimensional Fund Advisors LP Purchases 292,172 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 07, 2024

Oct 05, 2024

Sei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 05, 2024

Oct 04, 2024

Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings By Investing.com - Investing.com Canada

Oct 04, 2024

Oct 03, 2024

Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings - Investing.com India

Oct 03, 2024